@article {Fulton-Howard2020.04.06.20052332, author = {Brian Fulton-Howard and Alison M. Goate and Robert P. Adelson and Jeremy Koppel and Marc L. Gordon and Alzheimer{\textquoteright}s Disease Genetics Consortium and Nir Barzilai and Gil Atzmon and Peter Davies and Yun Freudenberg-Hua}, title = {Greater Effect of Polygenic Risk Score for Alzheimer{\textquoteright}s Disease Among Younger Cases who are Apolipoprotein E-ε4 Carriers}, elocation-id = {2020.04.06.20052332}, year = {2020}, doi = {10.1101/2020.04.06.20052332}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {To evaluate how age and Apolipoprotein E-ε4 (APOE4) status interact with APOE- independent polygenic risk score (PRSnon-APOE), we estimated PRSnon-APOE in superagers (age >= 90 years, N=346), 89- controls (age 60-89, N=2,930) and Alzheimer{\textquoteright}s Disease (AD) cases (N=1,760). Employing superagers, we see a nearly five times greater odds ratio (OR) for AD comparing the top PRSnon-APOE decile to the lowest decile (OR=4.82, P=2.5{\texttimes}10-6), which is twice the OR as using 89- controls (OR=2.38, P=4.6{\texttimes}10-9). Thus PRSnon-APOE is correlated with age, which in turn is associated with APOE. Further exploring these relationships, we find that PRSnon-APOE modifies age-at-onset among APOE4 carriers, but not among non-carriers. More specifically, PRSnon-APOE in the top decile predicts an age-at-onset five years earlier compared to the lowest decile (70.1 vs 75.0 years; t-test P=2.4{\texttimes}10-5) among APOE4 carriers. This disproportionally large PRSnon-APOE among younger APOE4-positive cases is reflected in a significant statistical interaction between APOE4 status and age-at-onset (β=-0.02, P=4.8{\texttimes}10-3) as a predictor of PRSnon-APOE. Thus, the known AD risk variants are particularly detrimental in young APOE4 carriers.Disclosure Statement AMG has consulted for Eisai, Biogen, Pfizer, AbbVie, Cognition Therapeutics and GSK. She also served on the SAB at Denali Therapeutics from 2015-2018. YFH co-owns stock and stock options of Regeneron Pharmaceuticals. All other authors have no interests to declare.Competing Interest StatementAMG has consulted for Eisai, Biogen, Pfizer, AbbVie, Cognition Therapeutics and GSK. She also served on the SAB at Denali Therapeutics from 2015-2018. YFH co-owns stock and stock options of Regeneron Pharmaceuticals. All other authors have no interests to declare.Funding StatementThis work was supported by the National Institutes of Health, National Institute on Aging (NIH-NIA) (ADGC and grant numbers U01 AG032984 and RC2 AG036528). Samples from the National Cell Repository for Alzheimer{\textquoteright}s Disease (NCRAD), which receives government support under a cooperative agreement awarded by the NIH-NIA (grant number U24 AG21886), were used in this study. The NACC database is funded by the NIH-NIA (grant number U01 AG016976). Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer{\textquoteright}s Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (grant number U24-AG041689-01). In addition, this work was funded by the NIH (grant numbers U01AG052411, U01AG058635, K08AG054727, R01 AG618381, and R01 AG046949), and the Einstein Nathan Shock Center (grant number P30 AG038072). Additional support was provided by the Mildred and Frank Feinberg Family Foundation, the Advancing Women in Science and Medicine Foundation, and the JPB Foundation.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genetic data referred to in the manuscript will be made available in a suitable repository, and is available upon reasonable request made to the corresponding author following peer-reviewed publication of the manuscript.}, URL = {https://www.medrxiv.org/content/early/2020/09/14/2020.04.06.20052332}, eprint = {https://www.medrxiv.org/content/early/2020/09/14/2020.04.06.20052332.full.pdf}, journal = {medRxiv} }